News summaryThe Motley FoolNov 9, 2026, 08:05 PM
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Moderna reported nearly $1.3 billion in third-quarter revenue, up from just under $1 billion a year earlier. [[fact:fact-a65l5pgd6]] COVID-related revenue accounted for 98% of its top line, with the remainder from its RSV vaccine. [[fact:fact-97787o4pv]] Updated guidance calls for full-year revenue growth of 15% to 25%. [[fact:fact-fdxwr4cdz]] The article's author says Moderna shares are not a buy at the current valuation and are a very risky holding. [[fact:fact-a5ixis9hy]]